Gyre Therapeutics sets CEO Ying Luo’s annual base salary at $500,000
GYRE•Gyre Therapeutics entered new employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 2026. Luo’s annual base salary is $500,000, while Eastling’s is $339,066.
1. Employment terms
Luo’s agreement sets a 2026 target bonus of $150,000. Eastling’s agreement sets a target bonus of $70,000.
2. Termination provisions
A termination without cause or resignation for good reason triggers six months of base salary, COBRA reimbursement and partial accelerated equity vesting. Qualifying terminations within three months before or 12 months after a change of control trigger lump-sum salary-and-bonus payments and full equity vesting.
